A hostile response to the USPTO’s guidelines

Anyone who attended the 2014 BIO International Convention in San Diego in June was left in no doubt about which subject is dominating discussion among IP lawyers working in the life sciences: the patent eligibility of natural products in the US following the Myriad and Mayo cases.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Natera and a rival draw the line under five-year fight

27 February 2026 The companies have agreed to dismiss their long-running patent fight over tumour-informed liquid biopsy technology, closing a high-stakes chapter in the fast-growing MRD testing market—while leaving the door open to future claims.

Americas

SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling

26 February 2026 As the US Supreme Court prepares to hear arguments in the Hikma and Amarin dispute, the case has drawn a broad coalition of industry support—including the US government and a co-author of the Hatch-Waxman Act itself.

Americas

Eli Lilly escapes $278m payout in biotech licensing dispute

26 February 2026 In a decision with implications for biotechnology licensing and pharmaceutical manufacturing, the Ninth Circuit has rejected a ‘sweeping’ royalty trigger from a lower court.

More features

Natera and a rival draw the line under five-year fight

SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling

Eli Lilly escapes $278m payout in biotech licensing dispute

Novo battles for GLP-1 leadership with fresh lawsuit and slashed prices

Wiggin’s new litigation partner deepens ‘technically complex’ offer

Could everyday hospital equipment be the next defence against counterfeit medicines?

BioNTech fires shots at Moderna's next-generation vaccine

Mintz gains ex-Winston & Strawn partner and ITC expert

A hostile response to the USPTO’s guidelines

More on this story

Editor's picks

Editor's picks

More features